TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1289369
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) with topical polymyxin, amphotericin B, and tobramycin throughout ITU stay, and intravenous ceftazidime for the first 3 days only.
Study: 1289369
Drug: Contemporaneous control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contemporaneous control (CC)
Study: 1289369
Drug: SDD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD and CC groups
Study: 4081704
Drug: M‐M‐RR II
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐M‐RR II vaccine
Study: 30376687
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy with estrogen and progestin
Study: 27220529
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with infrared laser to two forehead sites while seated (total 8 min, 1064 nm continuous wave, 250 mW/cm(2), 60 J/cm(2) per site of 13.6 cm(2))
Study: 27220529
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (LLLT + EX)
Study: 8594267
Drug: Oral beta
Normalized name: Cloral betaine
DrugBank: Chloral betaine (DB01494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta carotene, 50 mg per day for a median of 4.3 years
Study: 8594267
Drug: Initial plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial plasma beta carotene concentrations in the highest quartile (>0.52 micromol/L)
Study: 25045434
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Megestrol Acetate (MA) - 160 mg of MA daily plus 0.5 g of metformin thrice daily
Study: 25045434
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol Acetate (MA) alone - 160 mg of MA daily
Study: 19414708
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of antidepressant response
Study: 15451222
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg per month
Study: 9886730
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training group (daily exercise training for 3 months)
Study: 2591384
Drug: iopentol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol 0.3 g I/kg
Study: 2591384
Drug: iopentol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol 0.6 g I/kg
Study: 2591384
Drug: iopentol 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol 1.2 g I/kg
Study: 778307
Drug: Ribavirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (200 mg, three times daily)
Study: 778307
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg, twice daily)
Study: 26566148
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + Amiodarone
Study: 26341218
Drug: SUPER algorithm
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPER algorithm for early administration of analgesic drugs
Study: 26341218
Drug: Normal process
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal process of access to pain-control drugs (Group A)
Study: 20806117
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg twice daily
Study: 23451769
Drug: Apixaban 25
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 25 mg twice daily
Study: 23451769
Drug: Apixaban 25
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 25 mg once daily
Study: 22184801
Drug: Micronutrient combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient combination (vitamins C and D3, folic acid, and selenium)
Study: 20578847
Drug: 3-day per
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day per week take-home dosing schedule
Study: 20578847
Drug: 3-day per
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day per week clinic dosing schedule
Study: 20578847
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing schedule
Study: 20578847
Drug: 3-day per
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day per week supervised dosing
Study: 9252908
Drug: Cisapride, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 0.2 mg/kg three times daily
Study: 8296578
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (imipramine, clomipramine, desipramine)
Study: 3520319
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin during labor
Study: 25753932
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioral treatment (CBT) for high anxiety sensitivity, delivered over eight weeks.
Study: 24184053
Drug: PST (periosteal
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST (periosteal stimulation therapy) once a week for 10 weeks followed by PST boosters for 6 months
Study: 18787510
Drug: IV PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PTX 500 mg bolus followed by IV infusion of PTX 700 mg for two hours
Study: 15192991
Drug: ROI measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROI measurement in physical therapy clinical program
Study: 9284714
Drug: SRIH infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRIH infusion (90‐min iv infusion of SRIH at a rate of 9 micrograms/kg.h)
Study: 9284714
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (90‐min iv infusion of isovolumetric amounts of 0.9% saline)
Study: 9284714
Drug: SRIH infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRIH infusion
Study: 3532693
Drug: Fractionated diazoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated diazoxide administered intravenously (n = 28)
Study: 3532693
Drug: Dihydralazine administered
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine administered intramuscularly (n = 24)
Study: 3532693
Drug: Both drug
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drug regimens (diazoxide and dihydralazine)
Study: 3532693
Drug: Furosemide administered
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide administered intravenously (40 mg)
Study: 29441952
Drug: O/V ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: O/V ointment with 2% silver fir bark extract
Study: 27646425
Drug: Baseline CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CRP levels ≤ 3.0mg/L
Study: 27646425
Drug: Moderately/markedly elevated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately/markedly elevated CRP levels (≥6.9mg/L; 24% of patients)
Study: 24676963
Drug: Maintenance cognitive
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance cognitive stimulation therapy (CST) weekly group programme for 24 weeks
Study: 24676963
Drug: Maintenance cognitive
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance cognitive stimulation therapy (CST) weekly group programme for 24 weeks (subgroup taking AChEIs)
Study: 22627378
Drug: Ductal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ductal Injection (DI) with Serva collagenase
Study: 22627378
Drug: Ductal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ductal Injection (DI) with Liberase MTF
Study: 22627378
Drug: No Ductal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Ductal Injection (no DI)
Study: 19915202
Drug: EPA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1.6 g/day) and DHA (1.2 g/day)
Study: 19915202
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil (2.4 ml/day)
Study: 18076918
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of epirubicin plus oral administration of Lactobacillus casei preparation (3 gm per day for 1 year)
Study: 18076918
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of epirubicin (30 mg/30 ml saline twice during 1 week, plus 6 additional instillations during 3 months)
Study: 3283624
Drug: MP induction
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP induction treatment every 6 months
Study: 3283624
Drug: VCMP induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCMP induction treatment every 6 months
Study: 3283624
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment using the induction scheme Q 8 weeks
Study: 3283624
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy after remission induction
Study: 30937935
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin (INR: 2.0-3.0)
Study: 11194089
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg) plus placebo
Study: 11194089
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg) plus placebo
Study: 27060151
Drug: Bortezomib-dexamethasone therapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-dexamethasone therapy
Study: 18671197
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of Ageratina pichinchensis extract (phytopharmaceutical formulation in lacquer solution) for 6 months
Study: 18671197
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 8% ciclopirox lacquer solution for 6 months
Study: 16860051
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate gel, 3.5 ml, vaginally, bid, for 14 days
Study: 16860051
Drug: K-Y Jelly,
Normalized name: K-Y Jelly, topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Y Jelly, 3.5 ml, vaginally, bid, for 14 days
Study: 16860051
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate gel and K-Y Jelly
Study: 8853755
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg morning dosing
Study: 8853755
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg evening dosing
Study: 1735345
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg three times a day for 30 days)
Study: 6715083
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg metildigoxin (Lanitop)
Study: 6715083
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg beta‐acetyldigoxin (Novodigal)
Study: 24521088
Drug: Alters who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alters who did not use drugs
Study: 20657257
Drug: BBS (antibiotic-impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBS (antibiotic-impregnated bioabsorbable bone substitute)
Study: 20657257
Drug: PMMA (antibiotic-impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMMA (antibiotic-impregnated polymethylmethacrylate cement beads)
Study: 17482880
Drug: Escalated-dose CFRT
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated-dose CFRT
Study: 17482880
Drug: Standard-dose CFRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CFRT
Study: 12085202
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy followed by tamoxifen
Study: 12085202
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy followed by tamoxifen
Study: 26549586
Drug: Intravenous PEG-asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PEG-asparaginase (15 doses of 2500 IU/m² every 2 weeks)
Study: 26549586
Drug: Intramuscular native
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular native E coli L-asparaginase (30 doses of 25,000 IU/m² weekly)
Study: 26549586
Drug: Intravenous PEG-asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PEG-asparaginase
Study: 26549586
Drug: Intramuscular native
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular native E coli L-asparaginase
Study: 20733274
Drug: Oxandrolone (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.06 mg/kg/day) with Growth Hormone (GH 0.35 mg/kg/week)
Study: 20733274
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH 0.35 mg/kg/week) with Placebo (Pl)
Study: 19339393
Drug: Diet of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet of 5 servings of vegetables and fruit daily (Control)
Study: 12818944
Drug: Subarachnoid isobaric
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid isobaric lidocaine 30 mg
Study: 12818944
Drug: Subarachnoid hyperbaric
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid hyperbaric bupivacaine 5.25 mg
Study: 10890135
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg mefloquine administered on days 0, 1, 7, 14, 21 and 28; further 5 weekly doses of 250 mg mefloquine.
Study: 10890135
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg mefloquine administered as further 5 weekly doses.
Study: 8851688
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg po at -60 min)
Study: 8851688
Drug: Salbutamol (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.08 mg/kg po at -60 min)
Study: 1635441
Drug: Bronchodilator
Normalized name: Bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator
Study: 6369532
Drug: Cefazolin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (0.5 g every 6 h for 4 days)
Study: 6369532
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g every 12 h for 2 days)
Study: 26137975
Drug: Atacicept (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (150 mg subcutaneous injections once weekly for 25 weeks)
Study: 18975334
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 5 mg orally, once daily
Study: 18975334
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiresorptive treatment)
Study: 16871061
Drug: Videotape-assisted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape-assisted oral feedback
Study: 11783101
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (CDDP)
Study: 9365765
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug regimens (albendazole plus metronidazole, sulphadiazine plus pyrimethamine, atovaquone, doxycycline plus nifuroxazide, itraconazole, flubendazole, chloroquine, paromomycin, sparfloxacin)
Study: 3305212
Drug: Sustained chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained chemotherapy
Study: 3305212
Drug: Multi-centre therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-centre therapy
Study: 25175842
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (100 mg)
Study: 25175842
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine (37.5 mg)
Study: 23050696
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (Lac) at 2 g/kg diet
Study: 23050696
Drug: Hydrated sodium
Normalized name: Hydrated sodium borate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrated sodium calcium aluminosilicate (HSCAS) at 2 g/kg diet
Study: 23050696
Drug: Mannan oligosaccharides
Normalized name: Konjac mannan
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannan oligosaccharides (MOS) at 2 g/kg diet
Study: 16547085
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: 2 g/kg/day of protein equivalent
Study: 16547085
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: 1.2 g/kg/day protein equivalent
Study: 12535038
Drug: 15 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg.kg‐1 magnesium in 30 ml 0.9% NaCl over 20 min
Study: 3552020
Drug: Hydroxychloroquine (HC)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HC) 400 mg daily for the first month, then 200 mg daily thereafter
Study: 28960254
Drug: JTE-052 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-052 ointment at 0.25%
Study: 28960254
Drug: JTE-052 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-052 ointment at 0.5%
Study: 28960254
Drug: JTE-052 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-052 ointment at 1%
Study: 28960254
Drug: JTE-052 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-052 ointment at 3%
Study: 29071930
Drug: Long-snake moxibustion
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-snake moxibustion treatment
Study: 29071930
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine (Yupingfeng Granules)
Study: 29071930
Drug: Moxibustion vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion vs Herbal medicine
Study: 12242598
Drug: Venoruton powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton powder 0.5 g
Study: 12242598
Drug: Venoruton powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton powder 1 g
Study: 12242598
Drug: Venoruton powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton powder 2 g
Study: 12242598
Drug: Venoruton powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton powder 4 g
Study: 12242598
Drug: Venoruton powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton powder (all doses)
Study: 7652030
Drug: Nicotine dose
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine dose (15 micrograms/kg, approx. 1.1 mg for average subject)
Study: 2761122
Drug: NaHCO3 (E)
Normalized name: NaHCO3
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaHCO3 (E) 0.2 g.kg‐1 body wt
Study: 326642
Drug: Loperamide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (6 mg daily)
Study: 7790550
Drug: Injection flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection flow: 4 ml/s (Protocol 3)
Study: 7790550
Drug: Injection flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection flow: 4 ml/s (60 ml) + 2 ml/s (40 ml) (Protocol 2)
Study: 7790550
Drug: Injection flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection flow: 2 ml/s (Protocol 1)
Study: 387496
Drug: Choline theophyllinate
Normalized name: Choline theophyllinate
DrugBank: Oxtriphylline (DB01303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline theophyllinate 400 mg
Study: 26313620
Drug: One Session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Session Treatment (OST) with e-therapy homework maintenance program over 4 weeks
Study: 23358514
Drug: CTD0.02 (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTD0.02 (0.02 mg CTD/kg body weight)
Study: 23358514
Drug: CTD1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTD1 (1 mg CTD/kg body weight)
Study: 23358514
Drug: CTD50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTD50 (50 mg CTD/kg body weight)
Study: 23358514
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg CTD/kg body weight)
Study: 16923699
Drug: Nebulized pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized pentoxifylline (PTXF) 20 mg/kg (spontaneous breathing) or 10 mg/kg (ventilatory support) every 6 hours for 3 days
Study: 16923699
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (DX) 0.25 mg/kg every 12 hours for 3 days
Study: 15059684
Drug: 4 units
Normalized name: Afrezza, 4 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 units of alcohol (4 UA: 32 g ethyl alcohol, 1203.8 kJ)
Study: 15059684
Drug: 1 unit
Normalized name: Autopen Cartridge 1 unit, 3 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 unit of alcohol (1 UA: 8 g ethyl alcohol, 498.2 kJ)
Study: 8167351
Drug: Busulfan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (16 mg/kg, n = 88)